<DOC>
	<DOC>NCT02947022</DOC>
	<brief_summary>Purpose: There are two goals we have for this prospective single arm study; to see an increase in the amount of gadolinium in 24 hour urine collection following each infusion treatment with Calcium and Zinc DTPA, and to see a reduction or elimination of gadolinium deposition disease (GDD) symptoms. Participants: Twenty (20) patients who are suffering from gadolinium deposition disease (GDD) Procedures: Over a series of three (3) treatment time-points patients will be treated with IV Ca-DTPA on day one, and Zn-DTPA on day two.</brief_summary>
	<brief_title>Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Arthralgia</mesh_term>
	<mesh_term>Hyperpigmentation</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Pentetic Acid</mesh_term>
	<mesh_term>Edetic Acid</mesh_term>
	<mesh_term>Zinc</mesh_term>
	<criteria>Exhibiting 3 or greater of the following symptoms which must be present after having been administered a GBCA: Cognitive disturbance Extremity pain Headache Chest wall pain Skin induration Skin hyperpigmentation Skin pain Arthralgia Pregnant or lactating Less than 18 years old No evidence of gadolinium (has to have shown previous demonstration of Gd by urine analysis or bone biopsy) Known connective tissue disease such as Systemic Lupus Erythematosus or Scleroderma Severe hemochromatosis or Wilson's disease Glomerular Filtration Rate (GFR) â‰¤ 60 Have had an investigational drug within last 30 days Unable to give written consent Multiple Sclerosis Chronic heart failure Cirrhosis of the liver</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>gadolinium</keyword>
	<keyword>deposition</keyword>
	<keyword>GBCA</keyword>
	<keyword>Extremity Pain</keyword>
	<keyword>Skin Pain</keyword>
	<keyword>Chest Wall Pain</keyword>
</DOC>